New on Hybridoma.com
“We have worked with [Curia] on a great many projects, including antibody discovery and characterization, various biological assays, and assay setup. Each time the team delivered great quality results that allowed us to make informed decisions and move projects forward. [Curia] is accommodating of our diverse and changing needs, flexible, and easy to work with. You also always deliver results on time. I will highly recommend you as a partner for the discovery and early development work.”
Curia’s Coronavirus Spike Protein Antibodies: A fresh quiver of arrows against the crowned invader!
Watch Webinar Now
As part of Curia’s ongoing effort to combat the COVID-19 pandemic, we have discovered a large collection of over 350 diverse antibodies against the SARS-CoV-2 spike protein. The SARS-CoV-2 spike protein initiates viral attachment via binding to human angiotensin-converting enzyme 2 (ACE2), thus presenting itself as a crucial candidate for COVID-19 therapeutics, diagnostics, and vaccines.
Following immunization of our immunologically diverse PentaMice®, antibodies were obtained using our hybridoma-based antibody recovery workflow. Based on extensive screening assays, Curia’s SARS-CoV-2 spike antibodies display a wide range of binding specificities and functional properties. The spike antibodies can be grouped according to reactivity profiles based on binding to the receptor binding domain (RBD) and/or S1 or S2 domains; blocking spike protein binding to the ACE2 receptor; neutralizing SARS-CoV-2 pseudovirus infection of ACE2+TMPRSS2+ target cells; and cross-reactivity (or lack thereof) with spike proteins from other coronaviruses (SARS, MERS, and HKU1).
The various reactivity and functional profiles are consistent with COVID-19 antibody therapy, prevention of SARS-CoV-2 infection, and selective SARS-CoV-2 detection diagnostics. These antibodies are available for licensing for either therapeutic or diagnostic application.